Search

Author/Creator Cascavilla, N.

1. "Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese". Issue 3 (March 2015)

Authors:
Mele, G.; Melpignano, A.; Quarta, G.; Palumbo, G.; Capalbo, S.; Falcone, A.; Cascavilla, N.; Palazzo, G.; Mazza, P.; Iannitto, E.; Curci, P.; Rizzi, R.; Specchia, G.; Rossini, B.; Pavone, V.; Ria, R.; Vacca, A.; Buquicchio, C.; Tarantini, G.; Minoia, C.
Journal:
Leukemia research
Issue:
Volume 39:Issue 3(2015:Mar.)
Page Start:
279
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R‐CVP WITH R‐CHOP AND R‐FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY. (June 2017)

Authors:
Luminari, S.; Tarantino, V.; Anastasia, A.; Boccomini, C.; Chiarenza, A.; Rigacci, L.; Angelucci, E.; Ferrari, A.; Pulsoni, A.; Rattotti, S.; Angrilli, F.; Gaidano, G.; Stelitano, C.; Bertoldero, G.; Cascavilla, N.; Salvi, F.; Ferreri, A.J.; Vallisa, D.; Balzarotti, M.; Cox, M.C.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
34
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P1084: CHECK-POINT INHIBITORS IN PATIENTS WITH RELAPSE/REFRACTORY HODGKIN'S LYMPHOMA: A RETROSPECTIVE ANALYSYS BY THE RETE EMATOLOGICA PUGLIESE (REP). (23rd June 2022)

Authors:
Gaudio, F.; Loseto, G.; Bozzoli, V.; Scalzulli, P. R.; Mazzone, A. M.; Tonialini, L.; Fesce, V.; Quintana, G.; De santis, G.; Masciopinto, P.; Arcuti, E.; Clemente, F.; Scardino, S.; Tarantini, G.; Pastore, D.; Melillo, L.; Pavone, V.; Mazza, P.; Carella, A. M.; Cascavilla, N.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
974
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL. (23rd June 2022)

Authors:
Alessandria, B.; Genuardi, E.; Civita, A. M.; Drandi, D.; Mantoan, B.; Ferrante, M.; Borriero, M.; Ragaini, S.; Bondielli, G.; Zaccaria, G. M.; Barbero, D.; Peri, V.; Hohaus, S.; Musuraca, G.; Cascavilla, N.; Ghiggi, C.; Tani, M.; Gaidano, G.; Volpetti, S.; Usai, S. V.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1130
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P564: FINAL RESULTS OF THE QOLESS AZA-AMLE RANDOMIZED TRIAL TO EVALUATE THE EFFICACY OF 5-AZA FOR POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA IN ELDERLY PATIENTS. (23rd June 2022)

Authors:
Oliva, E. N.; Salutari, P.; Di Raimondo, F.; Reda, G.; Capelli, D.; Iannì, G.; Tripepi, G.; Alati, C.; Mammì, C.; D'Errigo, M. G.; Niscola, P.; Selleri, C.; Musto, P.; Vigna, E.; Volpe, A.; Cascavilla, N.; Cannatà, M. C.; Mannina, D.; Candoni, A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
463
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS. (23rd June 2022)

Authors:
Bruzzese, A.; Derudas, D.; Galli, M.; Martino, E. A.; Rocco, S.; Conticello, C.; Califano, C.; Giuliani, N.; Mangicavalli, S.; Farina, G.; Lombardo, A.; Brunori, M.; Rossi, E.; Antonioli, E.; Ria, R.; Zambello, R.; Di Renzo, N.; Mele, G.; Marcacci, G.; Pietrantuono, G.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1856
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. PB2016: COMPARISON BETWEEN DRD VS KRD AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS IN FIRST RELAPSE: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP). (23rd June 2022)

Authors:
Mele, A.; Prete, E.; Citiso, S.; Mele, G.; Pastore, D.; Sgherza, N.; Curci, P.; Musto, P.; Falcone, A. P.; Cascavilla, N.; Germano, C.; Giuseppe, T.; Reddiconto, G.; Di Renzo, N.; Palazzo, G.; Mazza, P.; Rossini, B.; Guarini, A.; Palumbo, G.; Melillo, L. M. A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1887
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. POD24 AND CR30 ARE PROMISING SURROGATE ENDPOINTS FOR ASSESSING THE OUTCOME OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA ENROLLED IN THE FOLL05 TRIAL BY FIL. (June 2017)

Authors:
Luminari, S.; Marcheselli, L.; Manni, M.; Anastasia, A.; Vitolo, U.; Chiarenza, A.; Rigacci, L.; Angelucci, E.; Fama, A.; Pulsoni, A.; Rattotti, S.; Angrilli, F.; Gaidano, G.; Stelitano, C.; Bertoldero, G.; Cascavilla, N.; Salvi, F.; Ferreri, A.J.; Tarantino, V.; Bellei, M.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
228
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗